Using blood DNA tests to guide lung cancer treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and able to sign consent before any study tests.
- Have fully removed lung cancer surgery: T1–2 N0 M0 or T3/T4 with multiple areas, with complete resection.
- No prior chemotherapy or radiation for your resected lung cancer.
- Have a detectable ctDNA blood test result (using the RaDaR/Inivata test) before or after surgery.
- Have good general health and strength (ECOG 0–1) and a life expectancy of at least 24 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
This study uses a special blood test to track minimal residual disease (tiny amounts of cancer that may remain) in people with stage IIIB-C non-small cell lung cancer after they receive initial chemotherapy plus immunotherapy. It may help doctors understand whether this blood test can guide further care and improve outcomes.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This study uses a blood test (ctDNA) to help doctors decide if you need radiation after lung cancer surgery. The goal is to personalize your treatment and avoid unnecessary radiation.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.